The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Menveo Market Between 2026 And 2030?
Historically, the observed growth was propelled by the broadening of national immunization programs, previous outbreaks of meningococcal disease, progress in conjugate vaccine technology, heightened awareness of illnesses preventable by vaccines, and worldwide vaccination efforts.
The anticipated growth during the forecast period is propelled by heightened investments in vaccine development, a sharpened focus on preventing outbreaks, the broadening of immunization coverage for adults and adolescents, an uptick in demand for travel-related vaccinations, and the reinforcement of public health infrastructure.
Significant trends expected in the forecast period involve a greater uptake of conjugate vaccines, an increasing emphasis on proactive immunization programs, a rising need for adolescent and travel vaccinations, the expansion of multivalent vaccine coverage, and an enhanced commitment to public health readiness.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20153&type=smp
Which Growth Factors Are Strengthening The Menveo Market Landscape?
The increasing frequency of meningitis cases is anticipated to drive the expansion of the menveo market in the coming years. Meningitis, an infection, leads to inflammation of the protective membranes that envelop the brain and spinal cord, typically initiated by viral, bacterial, or fungal agents. The escalating incidence of meningitis is primarily influenced by factors such as heightened global movement and compromised immune systems, which elevate the chances of disease transmission. menveo plays a crucial role in public health by offering protection against various strains of Neisseria meningitidis, facilitating early prevention, curtailing disease spread, and diminishing the burden of invasive meningococcal infections. For example, in October 2025, as reported by the UK Health Security Agency, a UK-based government agency, a total of 378 invasive meningococcal disease (IMD) cases were confirmed in 2024–25. Consequently, the rising occurrence of meningitis is fueling the growth of the menveo market.
Menveo Market Driver: Impact Of Global Healthcare Infrastructure Expansion On Market Growth
How Are Different Segment Groups Identified Within The Menveo Market?
The menveo market covered in this report is segmented –
1) By Type of Vaccine: Conjugate Vaccine, Combination Vaccine
2) By Indication: Meningococcal Disease Prevention, Routine Immunization, Outbreak Control, Travel Vaccination
3) By Age Group: Infants and Young Children, Adolescents, Adults, Older Adults
4) By End User: Hospitals, Vaccination Clinics, Travel Clinics, Academic And Research Institutions, Military And Government Facilities
Which Trends Are Influencing The Expansion Of The Menveo Market?
A significant trend in the menveo market focuses on developing innovative vaccine formulations, such as single-vial, fully liquid preparations, to enhance user convenience, improve stability, and simplify the administration process. These single-vial, fully liquid formulations are pharmaceutical products that come pre-mixed and packaged in a single vial, with their active ingredients already dissolved in a liquid state, ready for immediate use. For instance, in November 2024, GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical company, secured approval from the European Commission (EC) for a new presentation of its meningococcal vaccine, Menveo, designed for active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The vaccine is now licensed for application in children aged two years and older, adolescents, and adults. The core aspects of this vaccine’s approval include its licensing for active immunization within the European Union for children from two years of age, adolescents, and adults, featuring a novel single-vial, fully liquid presentation that eliminates the requirement for reconstitution before use.
Who Are The Businesses Driving Activity In The Menveo Market?
Major companies operating in the menveo market are GlaxoSmithKline (GSK) Plc
Access The Complete Menveo Market Report:
https://www.thebusinessresearchcompany.com/report/menveo-global-market-report
Which Region Accounts For The Highest Share Of The Menveo Market?
North America was the largest region in the menveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model